SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02476851

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube Holder

This study evaluates whether whole blood transferred through the new POLFA needle assembly meets supernatant hemoglobin acceptability standards.

NCT02476851 Transmission, Blood, Recipient/Donor

2 Interventions

Name: POLFA (Needle Assembly)

Description: Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.

Type: Device

Supernatant Hemoglobin

Name: Kawasumi (Needle Assembly)

Description: Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.

Type: Device

Supernatant Hemoglobin


Primary Outcomes

Description: demonstrate within a 95% CI and 95% reliability that whole blood transferred to a Vacutainer® through the POLFA needle will have supernatant hemoglobin levels <100 mg/dL

Measure: Plasma supernatant hemoglobin

Time: within 1 month of enrollment

Single Group Assignment


There is one SNP

SNPs


1 G20210A

- Study donors must not have experienced any of the following: Physical trauma consistent with associated coagulopathy within the last 30 days, Surgery within the last 30 days, Known history of hypercoagulopathy (i.e., Factor V Leiden, Prothrombin G20210A, idiopathic venous thrombotic events, etc.). --- G20210A ---



HPO Nodes